QUESTLAB2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member QUESTLAB2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member QUESTLAB2024-01-012024-03-31in-bse-fin:OneOperatingExpenses03Member QUESTLAB2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member QUESTLAB2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member QUESTLAB2024-01-012024-03-31in-bse-fin:FourOperatingExpenses03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares QUESTLAB 2023-04-01 2024-03-31 INR Yearly true Cash Flow Indirect Audited Standalone 415457000.00 1720000.00 417177000.00 264290000.00 0.00 -124000.00 19592000.00 4403000.00 2601000.00 70089000.00 360851000.00 56326000.00 0.00 56326000.00 0.00 56326000.00 17549000.00 1037000.00 18585000.00 37741000.00 0.00 0.00 0.00 37741000.00 37741000.00 119376000.00 10 3.41 3.41 0.00 0.00 0.00 Notes: 1.The above Standalone Financial Results for the Half Year and Year Ended 31stMarch, 2024 have been reviewed by Audit Committee and taken on record by the Board of Directors of Quest Laboratories Ltd. ( The Company ) in its meeting held on 30th May, 2024. 2. The Statutory Auditors of the Company have carried out the Audit of the standalone financial results for the Half year and year ended on 31stMarch, 2024. The figures for the half year ending 31stMarch,2023 have not been subjected to audit . The Management has exercised necessary due diligence to ensure that such financial results provide a true & fair view of the affairs of the Company. 3. The Company is primarily engaged in business of manufacturing drugs & medicine which constitute a single reportable segment. 4. The Company has allotted of 97,08,840 bonus equity shares of Rs. 10/- each as fully paid-up against existing 10,78,760 equity shares of Rs.10/- each to the existing shareholders of the Company in the ratio of 9:1, Also the company issued 11,50,000 shares on Rights basis. 5. Figures of the Half year ended 31st March, 2024 are the balancing figures between Audited figures in respect of the full financial year. 6. The previous period figures have been regrouped/ reclassified wherever necessary to make them comparable with the current periods figures. 7. Basic and Diluted EPS have been calculated using the weighted average number of shares. 8. The Company got listed on NSE-Emerge platform on 24th May, 2024. 31.03.2024 2023-2024 Debt Equity Ratio 0.04 0.04 Debt Service coverage ratio 21.08 26.92 Interest coverage Ratio 13.79 19.91 Audited Standalone 825628000.00 2291000.00 827919000.00 522896000.00 0.00 -444000.00 42734000.00 7640000.00 5678000.00 104956000.00 683460000.00 144459000.00 0.00 144459000.00 0.00 144459000.00 42067000.00 1454000.00 43521000.00 100939000.00 0.00 0.00 0.00 1009.39 100939000.00 119376000.00 10 167058000.00 9.11 9.11 0.00 0.00 0.00 Administrative Expenses 26276000.00 Manufacturing Expenses 7958000.00 Selling and Distribution expenses 35855000.00 Administrative Expenses 36165000.00 Manufacturing Expenses 13985000.00 Selling and Distribution expenses 54806000.00 5348000.00 5678000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11026000.00 -49656000.00 -34704000.00 8009000.00 -49917000.00 16306000.00 26676000.00 -83286000.00 -72260000.00 72199000.00 0.00 0.00 0.00 -42067000.00 0.00 114266000.00 0.00 0.00 114266000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -9399000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2291000.00 0.00 43185000.00 0.00 50293000.00 0.00 0.00 50293000.00 -34500000.00 0.00 0.00 0.00 -6466000.00 0.00 -7640000.00 0.00 0.00 -20394000.00 0.00 0.00 -20394000.00 144165000.00 0.00 144165000.00 1202000.00 145367000.00